Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Safety and Efficacy of BFH772 in Psoriasis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00987870
Recruitment Status : Completed
First Posted : October 1, 2009
Last Update Posted : March 28, 2011
Information provided by:

Brief Summary:
This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.

Condition or disease Intervention/treatment Phase
Psoriasis Arthritis Drug: BFH772 Drug: Placebo Drug: calcipotriol/betamethasone Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Proof of Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Topical Administrations of BFH772 in Patients With Psoriasis.
Study Start Date : September 2009
Actual Primary Completion Date : February 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: BFH772 cream 1% Drug: BFH772
Placebo Comparator: Placebo to BFH772 cream 1% Drug: Placebo
Experimental: BFH772 ointment 1% Drug: BFH772
Placebo Comparator: Placebo to BFH772 ointment Drug: Placebo
Active Comparator: calcipotriol/betamethasone ointment Drug: calcipotriol/betamethasone

Primary Outcome Measures :
  1. Measure: Plaque PASI score [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Measure: Local tolerability [ Time Frame: Time Frame: baseline (predose Day 1) and 1h, 3h, 6h after the morning dose, then before each application (morning and evening) until the morning application on Day 5 and then at each visit before the morning application, and at study completion ]
  2. Measure: BFH772 concentration in plasma [ Time Frame: Day 1: Pre-dose; 4h post dose. ]
  3. Measure: BFH772 concentration in skin [ Time Frame: Week 4 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stable mild to moderate plaque psoriasis (BSA involvement < 10% or PASI < 10
  • Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthritis
  • Diagnosed or history of psoriasis for at least 6 months prior to screening

Exclusion Criteria:

  • Nonplaque forms of psoriasis
  • Drug-induced psoriasis
  • Current use of beta blockers
  • Congestive heart failure (NYHA >III), QT interval >450msec or poorly controlled diabetes mellitus

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00987870

Layout table for location information
Novartis Investigator Site
Berlin, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00987870    
Other Study ID Numbers: CBFH772A2201
EUDRACT No. 2008-002795-96
First Posted: October 1, 2009    Key Record Dates
Last Update Posted: March 28, 2011
Last Verified: March 2011
Keywords provided by Novartis:
Stable plaque Psoriasis
inflammatory skin
with or without arthritis
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Betamethasone Valerate
Betamethasone benzoate
Betamethasone sodium phosphate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents